Silence Therapeutics (SLN) Return on Equity: 2021-2025
Historic Return on Equity for Silence Therapeutics (SLN) over the last 1 years, with Sep 2025 value amounting to -0.77%.
- Silence Therapeutics' Return on Equity was N/A to -0.77% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.77%, marking a year-over-year change of. This contributed to the annual value of -0.58% for FY2024, which is 162.00% up from last year.
- Per Silence Therapeutics' latest filing, its Return on Equity stood at -0.77% for Q3 2025, which was down 0.32% from -0.76% recorded in Q2 2025.
- Silence Therapeutics' 5-year Return on Equity high stood at -0.35% for Q4 2024, and its period low was -7.40% during Q1 2022.
- Over the past 3 years, Silence Therapeutics' median Return on Equity value was -0.67% (recorded in 2025), while the average stood at -0.94%.
- As far as peak fluctuations go, Silence Therapeutics' Return on Equity skyrocketed by 476bps in 2023, and later declined by 3bps in 2025.
- Quarterly analysis of 5 years shows Silence Therapeutics' Return on Equity stood at -3.71% in 2021, then reached -7.40% in 2022, then soared by 476bps to -2.65% in 2023, then spiked by 209bps to -0.35% in 2024, then declined by 3bps to -0.77% in 2025.
- Its last three reported values are -0.77% in Q3 2025, -0.76% for Q2 2025, and -0.58% during Q1 2025.